logo
  

SandRidge's MidCon Midstream Files Registration Statement For IPO

SandRidge Energy Inc.'s (SD) subsidiary MidCon Midstream, LP has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission or "SEC" regarding its proposed initial public offering of common units representing limited partner interests. MidCon Midstream is a Delaware limited partnership recently formed by SandRidge to own, operate, acquire and develop assets used to gather, process and dispose of saltwater produced alongside oil and natural gas. MidCon Midstream anticipates that its initial assets would include well connections, gathering pipelines and disposal wells in the Mid-Continent region of the U.S.

The number of common units to be offered and the offering's price range were not determined. MidCon Midstream plans to apply for a listing of the common units on the New York Stock Exchange. SandRidge would own the general partner of MidCon Midstream and all of its incentive distribution rights and expects to initially retain a majority of MidCon Midstream's units representing limited partner interests. The company said that a substantial majority of the net proceeds of the offering is likely to be distributed to SandRidge.

BofA Merrill Lynch and Barclays would act as the joint book-running managers for the proposed offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT